RenovoRx (RNXT)
Develops targeted intra-arterial chemotherapy and commercializes the RenovoCath delivery device.
$1.62
vs last close−0.08 (−4.71%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 20.38% | 9.20M shares | |
|---|---|---|---|
| 29 holders · as of Jun 30, 2026 | |||
| Insiders | 14.15% | 6.39M shares | |
| 7 holders · as of Sep 15, 2026 | |||
| Other | 65.47% | 29.54M shares | |
| remainder | |||
45.13M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
29 holders · 9.20M shares · 4 new positions · 12 increased · 6 reduced · 6 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Aigh Capital Management LLC | 4.41M | 9.76% | +699.2K | Aug 7, 2026 |
| Bleichroeder LP | 1.67M | 3.69% | 0 | Aug 13, 2026 |
| Vanguard Capital Management LLC | 1.44M | 3.20% | −3.4K | Aug 13, 2026 |
| Geode Capital Management, LLC | 424.1K | 0.94% | +42.4K | Aug 12, 2026 |
| Wealthspire Advisors, LLC | 252.5K | 0.56% | 0 | Aug 11, 2026 |
| Vanguard Fiduciary Trust Co | 240.3K | 0.53% | +82.4K | Aug 13, 2026 |
| Citadel Advisors LLC | 133.6K | 0.30% | −99.1K | Sep 2, 2026 |
| Chicago Partners Investment Group LLC | 92.4K | 0.20% | 0 | Jul 30, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Orin Hirschman | 9.80% | 4.43M | 13G | Apr 27, 2026 |
| Hirschman Orin | 9.50% | 3.47M | 13G | May 8, 2025 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| May 19, 2026 | Mark Vollofficer: Chief Financial Officer | Purchase | 25,000 | $0.7876 | 142,380 |
| Mar 20, 2026 | Mark Vollofficer: Chief Financial Officer | Purchase · 2 lots | 145,800 | $1.93 | 145,800 |
| Mar 20, 2026 | Shaun Bagaidirector, officer: Chief Executive Officer | Purchase · 2 lots | 36,450 | $1.93 | 325,507 |
| Mar 20, 2026 | Laurence Martondirector | Purchase · 2 lots | 14,580 | $1.93 | 14,580 |
| Jan 21, 2026 | Ramtin Agahdirector, officer: Chief Medical Officer | Purchase | 10,000 | $0.9975 | 798,460 |
| Dec 31, 2025 | Ramtin Agahdirector, officer: Chief Medical Officer | Purchase | 9,795 | $0.8600 | 788,460 |
| Dec 30, 2025 | Ramtin Agahdirector, officer: Chief Medical Officer | Purchase | 205 | $0.8260 | 778,665 |
| Dec 18, 2025 | Shaun Bagaidirector, officer: Chief Executive Officer | Purchase | 5,000 | $0.9013 | 340,040 |
| Dec 17, 2025 | Shaun Bagaidirector, officer: Chief Executive Officer | Purchase | 5,000 | $0.8524 | 335,040 |
| Dec 16, 2025 | Ramtin Agahdirector, officer: Chief Medical Officer | Purchase | 12,000 | $0.8500 | 778,460 |
House and Senate disclosures
Not reported.